These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20938713)

  • 1. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
    Ramaswamy B; Phelps MA; Baiocchi R; Bekaii-Saab T; Ni W; Lai JP; Wolfson A; Lustberg ME; Wei L; Wilkins D; Campbell A; Arbogast D; Doyle A; Byrd JC; Grever MR; Shah MH
    Invest New Drugs; 2012 Apr; 30(2):629-38. PubMed ID: 20938713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
    Phelps MA; Lin TS; Johnson AJ; Hurh E; Rozewski DM; Farley KL; Wu D; Blum KA; Fischer B; Mitchell SM; Moran ME; Brooker-McEldowney M; Heerema NA; Jarjoura D; Schaaf LJ; Byrd JC; Grever MR; Dalton JT
    Blood; 2009 Mar; 113(12):2637-45. PubMed ID: 18981292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
    Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
    J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
    Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M; Broering S; Schaaf LJ; Johnson AJ; Lucas DM; Heerema NA; Lozanski G; Young DC; Suarez JR; Colevas AD; Grever MR
    Blood; 2007 Jan; 109(2):399-404. PubMed ID: 17003373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
    Dickson MA; Shah MA; Rathkopf D; Tse A; Carvajal RD; Wu N; Lefkowitz RA; Gonen M; Cane LM; Dials HJ; Schwartz GK
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1113-21. PubMed ID: 20953860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
    Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
    J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
    Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.
    Blum W; Phelps MA; Klisovic RB; Rozewski DM; Ni W; Albanese KA; Rovin B; Kefauver C; Devine SM; Lucas DM; Johnson A; Schaaf LJ; Byrd JC; Marcucci G; Grever MR
    Haematologica; 2010 Jul; 95(7):1098-105. PubMed ID: 20460644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
    LaCerte C; Ivaturi V; Gobburu J; Greer JM; Doyle LA; Wright JJ; Karp JE; Rudek MA
    Clin Cancer Res; 2017 Jul; 23(14):3592-3600. PubMed ID: 28174232
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
    Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
    J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
    Lin TS; Ruppert AS; Johnson AJ; Fischer B; Heerema NA; Andritsos LA; Blum KA; Flynn JM; Jones JA; Hu W; Moran ME; Mitchell SM; Smith LL; Wagner AJ; Raymond CA; Schaaf LJ; Phelps MA; Villalona-Calero MA; Grever MR; Byrd JC
    J Clin Oncol; 2009 Dec; 27(35):6012-8. PubMed ID: 19826119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of flavopiridol in relapsed multiple myeloma.
    Hofmeister CC; Poi M; Bowers MA; Zhao W; Phelps MA; Benson DM; Kraut EH; Farag S; Efebera YA; Sexton J; Lin TS; Grever M; Byrd JC
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):249-57. PubMed ID: 24241210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
    Shah MA; Kortmansky J; Motwani M; Drobnjak M; Gonen M; Yi S; Weyerbacher A; Cordon-Cardo C; Lefkowitz R; Brenner B; O'Reilly E; Saltz L; Tong W; Kelsen DP; Schwartz GK
    Clin Cancer Res; 2005 May; 11(10):3836-45. PubMed ID: 15897584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.
    Dickson MA; Rathkopf DE; Carvajal RD; Grant S; Roberts JD; Reid JM; Ames MM; McGovern RM; Lefkowitz RA; Gonen M; Cane LM; Dials HJ; Schwartz GK
    Invest New Drugs; 2011 Oct; 29(5):1004-12. PubMed ID: 20461440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.
    Zhai S; Sausville EA; Senderowicz AM; Ando Y; Headlee D; Messmann RA; Arbuck S; Murgo AJ; Melillo G; Fuse E; Figg WD
    Anticancer Drugs; 2003 Feb; 14(2):125-35. PubMed ID: 12569299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.
    Mahadevan D; Plummer R; Squires MS; Rensvold D; Kurtin S; Pretzinger C; Dragovich T; Adams J; Lock V; Smith DM; Von Hoff D; Calvert H
    Ann Oncol; 2011 Sep; 22(9):2137-2143. PubMed ID: 21325451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
    Bible KC; Lensing JL; Nelson SA; Lee YK; Reid JM; Ames MM; Isham CR; Piens J; Rubin SL; Rubin J; Kaufmann SH; Atherton PJ; Sloan JA; Daiss MK; Adjei AA; Erlichman C
    Clin Cancer Res; 2005 Aug; 11(16):5935-41. PubMed ID: 16115936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
    Fornier MN; Rathkopf D; Shah M; Patil S; O'Reilly E; Tse AN; Hudis C; Lefkowitz R; Kelsen DP; Schwartz GK
    Clin Cancer Res; 2007 Oct; 13(19):5841-6. PubMed ID: 17908977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of flavopiridol in patients with advanced colorectal cancer.
    Aklilu M; Kindler HL; Donehower RC; Mani S; Vokes EE
    Ann Oncol; 2003 Aug; 14(8):1270-3. PubMed ID: 12881391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
    Rudek MA; Bauer KS; Lush RM; Stinson SF; Senderowicz AM; Headlee DJ; Arbuck SG; Cox MC; Murgo AJ; Sausville EA; Figg WD
    Ann Pharmacother; 2003 Oct; 37(10):1369-74. PubMed ID: 14519054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.